Introduction
Chronic hepatitis B (CHB) infection with hepatitis B virus (HBV) constitutes a global health burden, affecting 400 million patients [1] , and an estimated 600,000 people dying annually from CHB-related complications [2] . The last two decades have seen the introduction of various nucleoside/nucleotide analogs (NAs) [3] [4] [5] [6] [7] . There is increasing medical evidence supporting long-term NA therapy to maintain a permanent virologic suppression [8] , which could result in histologic improvement with reversal of fibrosis [9] and reduction in the incidence of cirrhotic complications and hepatocellular carcinoma (HCC) [10, 11] .
The prerequisites for long-term therapy include a simple dosing regimen to ensure drug compliance, satisfactory tolerability, minimal toxicity, favorable potency, and minimal drug resistance. Drug resistance is an important issue in NA therapy, especially with lamivudine, adefovir, and telbivudine [12] . Resistance to lamivudine can be B67% and [75% after 4 and 5 years of therapy, respectively [11, 13] . The cumulative resistance rate of telbivudine is 34% after 3 years [14] . Both lamivudine and telbivudine have a low genetic barrier to resistance, with only one mutation at the rtM204 V/I locus required. The acyclic structure of adefovir has a high molecular flexibility, resulting in effective drug action even when there are minor alterations in the binding pocket as a result of viral mutations [15] . Despite this molecular advantage, the resistance rate to adefovir is still 22% after 2 years of therapy [16] , with mutations at the rtA181T and rtN236T loci.
An ideal NA would need to have a durable antiviral potency and also a high genetic barrier of resistance. Entecavir was the first drug with such favorable properties, with only 1.2% resistance rate after 5 years of therapy in treatment-naive CHB patients [17, 18] . However, the results in lamivudine-resistant patients are sub-optimal, with 51% resistance rate after 5 years of therapy [17, 19] . This review discusses another potent NA recently available for CHB treatment: tenofovir disoproxil fumarate (TDF).
Early observational studies
TDF is an orally bioavailable prodrug of tenofovir [20] , which belongs to a class of drugs known as acyclic nucleoside phosphonates [21] , known for their potent antiviral activity against both DNA and RNA viruses through direct binding with the viral polymerases. TDF was first approved by the US Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus (HIV) infection in 2001, and has since become the cornerstone for anti-HIV combination treatment regimens. TDF is also active against HBV, with in vitro studies showing potent antiviral activity against both wild-type and lamivudine-resistant HBV [22] . Tenofovir is converted to its active form through a two-step phosphorylation, and terminates chain elongation catalyzed by the HBV DNA polymerase.
The initial clinical evidence of TDF in the treatment of CHB arose from HIV-HBV co-infected individuals. In 2002, van Bommel et al. [23] treated five lamivudine-resistant HBV-HIV co-infected patients with TDF 300 mg daily, resulting in a 4.5 log reduction in HBV DNA by week 24. Two similar studies by Ristig et al. [24] and Benhamou et al. [25] in six and ten co-infected individuals, respectively, also had comparable findings, with serum HBV DNA decreasing by 4.3 and 3.8 logs, respectively, at week 24. Furthermore, the first comparative study in 12 co-infected individuals found TDF achieving better viral suppression when compared to placebo [26] . TDF was also found to achieve potent viral suppression in a small study of CHB patients with no HIV coinfection [27] , as well as in lamivudine-resistant patients following liver transplantation [28] .
The initial success of TDF led to comparative studies with adefovir dipivoxil, also an acyclic nucleoside phosphatase, which was approved by the US FDA for the treatment of CHB infection in 2002. Adefovir was mainly used as ''rescue'' therapy in lamivudine resistance [29, 30] , but its usage was hindered by the increased frequency of adefovir-resistance mutations when compared to NA-naive patients [31] . In the first study comparing TDF and adefovir [32] , 53 lamivudine-resistant HBV patients were treated with TDF 300 mg daily or adefovir 10 mg daily for B130 weeks. The majority of patients had HIV coinfection. TDF was shown to achieve a faster HBV DNA reduction by week 4 when compared to adefovir, with the HBV DNA reduction becoming significantly better than adefovir by week 12. All patients on TDF achieved undetectable HBV DNA (\69 IU/mL) at week 48, compared to 44% of patients on adefovir. There was no evidence of phenotypic viral resistance to TDF up to week 130. Despite the similar molecular structure of TDF and adefovir, TDF was also effective in patients with sub-optimal virologic response to adefovir [33] .
Clinical trials of TDF in CHB
From the above observational studies, based on its antiviral potency, minimal resistance, and effectiveness in lamivudine-resistant patients, TDF has the potential to become the ''ideal'' drug for CHB. This had led to the commencement of different clinical trials in both treatment-naive and NAexperienced CHB patients (Table 1) .
Marcellin et al. [34] conducted the first randomized double-blind study concerning TDF, in both hepatitis B e antigen (HBeAg)-positive (study 103) and -negative (study 102) patients with compensated liver disease randomly assigned to receive either TDF (n = 426) or adefovir (n = 215) for 48 weeks [34] . A small proportion of patients was previously treated with lamivudine, emtricitabine, or interferon. The primary endpoint was a serum HBV DNA level of \69 IU/mL (or 400 copies/mL). By weeks 4-12, there was already an obvious difference in viral suppression between the two treatment groups. By week 48, significantly more patients on TDF achieved HBV DNA undetectability (76% for HBeAg-positive, 93% for HBeAg-negative) when compared to those on adefovir (13 and 63%, respectively). Of HBeAg-positive patients on TDF, 3% achieved hepatitis B surface antigen (HBsAg) seroclearance, while histologic improvements were similar in both treatment groups. Tenofovir produced similar viral suppression in patients with prior lamivudine treatment.
Patients from the above studies, irrespective of their therapeutic response, were enrolled in a follow-up study to receive open-label TDF for 7 years more [35] . Patients from both groups with detectable serum HBV DNA at week 72 were eligible to receive tenofovir together with emtricitabine at the discretion of the investigators. The primary endpoints were the serologic and virologic outcomes and the resistance profile at week 144 (n = 542). Up to 72 and 87% of HBeAg-positive and -negative patients, respectively, achieved undetectable HBV DNA (\69 IU/ mL) by week 144. Patients who were originally on adefovir and subsequently switched to TDF at week 48 also had similar outcomes. No resistance to tenofovir was detected. A cumulative 8% of HBeAg-positive patients (the majority being genotypes A and D) achieved HBsAg seroclearance, although there were no cases of HBsAg loss in HBeAgnegative patients. When the same patient cohort was followed up to week 192, rates of undetectable HBV DNA were 77 and 86% in HBeAg-positive and -negative patients, respectively. HBsAg seroclearance rate among HBeAg-positive patients increased to 10%, with 7.5% seroconverting to serum antibody to HBsAg (anti-HBs) [36, 37] . In a sub-group analysis of patients with high baseline viral load ([8.3 log IU/mL), [95% achieved undetectable HBV DNA and 15.2% of HBeAg-positive patients achieved HBsAg seroclearance [38] at week 192. Another sub-group analysis of 198 Asian CHB patients also found 79% (74% HBeAg-positive, 84% HBeAg-negative) achieving HBV DNA undetetectability at week 192, although there were no Asian patients achieving HBsAg seroclearance [39] . Of the 51 patients eligible for receiving combination of TDF and emtricitabine, 34 had combination therapy while 17 remained on TDF monotherapy. There was no difference in viral suppression between those receiving combination therapy and those who continued to receive TDF monotherapy for up to 3 years [35] .
TDF is also effective in patients with prior exposure to different NAs. A randomized double-blind study by Berg et al. in Europe [40] recruited patients with an incomplete virologic response to adefovir (n = 105), with 31 having proven adefovir-resistance mutations and 25 having lamivudine-resistance mutations. They were randomly assigned to either TDF or TDF plus emtricitabine group. At 48 weeks, 81% of patients in both treatment groups had HBV DNA levels of\69 IU/mL. A continued follow-up of the same patient cohort showed similar viral suppression (86%) up to week 168 [41] . Another prospective study by Patterson et al. in Australia [42] enrolled 60 patients with incomplete virologic response to both lamivudine and adefovir. After 96 weeks of TDF or combination of TDF and lamivudine, 64% of patients achieved HBV DNA levels of \15 IU/mL. Viral suppression was similar regardless of the addition of lamivudine. Both the European and Australian studies found treatment response to be independent of baseline mutations. A preliminary Italian study also showed similar findings [43] .
However, the above findings were not entirely reproduced in a retrospective multicenter study from Germany [44] , with 131 NA-experienced patients having previous treatment failure with lamivudine, adefovir, combination of lamivudine and adefovir, or entecavir. After a mean treatment duration of 23 months, 79% achieved a HBV DNA level \69 IU/mL. HBsAg seroclearance occurred in 3% of patients. Unlike the previous three studies, the presence of adefovir mutations impaired TDF efficacy when compared to the presence of lamivudine mutations (52 vs 100%, respectively, achieving viral suppression). The outcome of adefovir-resistant patients in different trials is shown in Table 2 . For all four studies, the number of patients with proven genotypic adefovir resistance is actually small. In addition, different resistance detection methods were used. Two of the four studies [42, 44] used only direct sequencing for resistance detection, a method that can detect mutations only if there are C20-30% of mutants circulating in the total viral population [45] . The other two studies [40, 43] used a line probe assay (LiPA), which is able to detect mutations constituting 5% of the total viral population [46] . Further studies with a larger study population are needed to determine the efficacy of TDF in adefovir-resistant patients.
Tenofovir in decompensated CHB
The use of NAs in decompensated CHB had previously shown mixed results. Lamivudine was able to improve liver function in decompensated CHB [47] , but evidence on its effect in improving survival has been mixed [48, 49] . The use of adefovir in decompensated CHB also improved liver function significantly; however, 14% of patients died within the first year and 33% still required liver transplantation for long-term survival [50] . Entecavir in decompensated CHB achieved an 87-91% 1-year patient survival [51, 52] . However, there was a report of five cases of lactic acidosis according to a study with limited number of patients [53] . The same center subsequently described similar cases of lactic acidosis with other NAs. There was also a possible increase in short-term mortality when used in acute exacerbation of CHB in a retrospective study comparing entecavir and lamivudine in 36 and 117 patients, respectively [54] . A recent study compared TDF (n = 45), emtricitabine/TDF (n = 45), and entecavir (n = 22) in patients with decompensated CHB for 48 weeks [52] . All three treatment arms had comparable biochemical and virologic improvements. Patients on TDF or emtricitabine/ TDF were more likely to achieve HBeAg loss. There were no cases of lactic acidosis reported for any treatment group.
Tenofovir in acute on chronic liver failure
A recent prospective study randomly assigned patients diagnosed with acute-on-chronic liver failure due to CHB to receive either TDF (n = 14) or placebo (n = 13) [55] . Patients were followed up for 3 months, with no liver transplantation offered due to its unavailability. Fifty-seven percent of patients on TDF survived compared to 15% on placebo. One patient on TDF developed HBsAg seroclearance. Patients on TDF also showed marked virologic and biochemical improvements, with a 2 log HBV DNA reduction within 2 weeks independently predicting survival. Despite its small sample size, the authors concluded that responders to TDF could be identified within 2 weeks, thus optimizing patient selection for liver transplantation. Prospective studies on a larger scale are needed to confirm this finding.
Tenofovir in solid organ transplant recipients
The use of TDF in solid organ transplant recipients has not been extensively studied, with most studies to date focusing on lamivudine.
A recent small study on seven transplant recipients with prior sub-optimal response to other NAs found TDF to be both efficacious and safe [56] . Another small study followed up eight patients with HBV recurrence after liver transplantation. Four patients had detectable viremia despite entecavir, and eventual viral suppression was achieved with the addition of TDF [57] . While more large-scale studies are required to determine efficacy and safety of TDF in this special group of patients, it would be reasonable to anticipate an optimal virologic response and low rate of resistance.
Resistance profile of tenofovir
To date, there are no reports of any virologic resistance to TDF among patients with CHB monoinfection. A phenotypic analysis with recombinant HBV was performed using serum derived from studies with 102 and 103 patients [34, 35] . The majority of these patients were NA-naive, and baseline genotypic mutations were found in only 1.1% of patients (all lamivudine-related rtM204 V/I with or without rtL180 M). Serum was chosen from patients who developed virologic breakthrough, although it was infrequent and found to be mostly associated with drug noncompliance. No patients developed amino acid substitutions associated with resistance to TDF up to week 144 [58] .
The first study to suggest mutation loci associated with TDF resistance was based on 43 CHB patients with HIV coinfection [59] . The rtA194T substitution in two patients was found to be associated with reduced susceptibility to TDF in vitro when the lamivudine mutations of rtM204V and rtL180M were present. Nevertheless, further studies concerning the rtA194T mutation showed mixed results. A subsequent in vitro study failed to reproduce the results of Sheldon et al. [59] . Another study using replicated HBV plasmid harboring rtA194T alone or with lamivudine-associated mutants found the rtA194T mutation to be associated with partial resistance to TDF; however, the effect on resistance is negated when the mutations occur together with precore or basic core promoter substitutions [61] .
The clinical impact of the rtA194T mutation is still unknown. A preliminary clinical study followed up ten CHB patients with the rtA194T mutation present before commencing on TDF. After receiving either TDF monotherapy or in combination with either lamivudine or emtricitabine for 1.5 years, all patients had C3 log reduction in DNA after 12 weeks, and nine patients achieved HBV DNA levels of \100 IU/mL at their last follow-up [62] .
In vitro studies had also found the adefovir-related mutations rtA181T and rtN236T to be associated with reduced susceptibility to TDF [63, 64] . As mentioned previously, clinical studies on the efficacy of TDF in adefovirresistant patients showed mixed results [40, [42] [43] [44] .
It is possible that TDF results in rapid viral suppression, thus preventing resistant strains with reduced replicative capacity from taking over the majority of the viral population, making the rtA194T, rtA181T, or the rtN236T mutations clinically irrelevant. More long-term studies with larger cohort of patients on TDF harboring the above mutations would be needed before definitive conclusions can be drawn.
Cost utility analysis of tenofovir
Data on the cost-effectiveness of TDF are emerging. A recent study from the UK investigated this issue, using a Markov model to compare TDF with lamivudine, adefovir, and entecavir. First-line TDF was found to be the most cost-effective treatment for patients with CHB, costing £19,084 per quality-adjusted life year gained compared with the next best alternative [65] . Another study compared the 12-month treatment outcomes of the five NAs and pegylated interferon in various randomized control trials using a Bayesian mixed treatment comparison model. TDF was found to be most cost-effective in HBeAg-negative disease [66] . Given its limited availability in Asia, similar cost-utility analysis of TDF in Asia is lacking, although a Hong Kong study on the cost-effectiveness of other NAs found TDF to be the most cost-effective if it was priced similarly to telbivudine [67] .
Safety
An understanding of the safety profile of TDF is essential, especially when NA therapy is likely to be long term, in order to achieve permanent viral suppression. The kidneys primarily excrete tenofovir, and the most important safety concern of TDF would be its association with renal dysfunction. The majority of cases with TDF-associated renal impairment were reported from the HIV population. Although less commonly seen when compared to adefovir therapy, prolonged treatment with TDF is associated with renal proximal tubular dysfunction [68] [69] [70] and hypophosphatemia, the latter secondary to reduced phosphate reabsorption and excessive loss of urinary phosphates [71] [72] [73] . Fanconi syndrome and acute renal failure have also been reported [74, 75] , although the nephrotoxicity is usually reversible when therapy is stopped. TDF is associated with a 4% decline in glomerular filtration rate (GFR) in HIV patients over 1 year [76] and a decline of 9.8 mL/ min/1.37 m 2 B5 years [77] , although given the differences in disease nature, such data might not be directly applicable in CHB.
Safety data of long-term TDF in CHB are emerging. In patients with HIV coinfection taking TDF, GFR declined by 22.19 ml/min/1.73 mm 2 from baseline over a median follow-up period of 251 weeks [78] . However, clinical trials of TDF in CHB monoinfection mentioned previously did not detect any significant changes in creatinine levels or creatinine clearance B144 weeks [35, 42, 44] . A preliminary Italian study followed 737 CHB patients on TDF for a median period of 16 months, of which 524 had prior exposure to other NAs. Less than 1% of patients had an increase in serum creatinine of[44 umol/L (or 0.5 mg/dL). In terms of tubular function, 37% patients had a significant decrease in urinary phosphate reabsorption, of which the majority had prior exposure to adefovir. The authors concluded that TDF had a favorable safety profile, with only a few patients (mainly NA-experienced) showing a mild degree of renal dysfunction [79] . TDF usage in decompensated liver disease is of special concern, especially since many such patients have concurrent renal impairment. In a study on patients with decompensated CHB, only 7.8% had an increase in serum creatinine of [44 umol/L after 48 weeks of TDF [52] , which was not significantly different from the 4.5% observed with entecavir in the same study. Dosage adjustments are required for patients with a creatinine clearance of \50 ml/min. TDF is taken at 300 mg every 48 h for patients with a creatinine clearance of 30-49 ml/min, and every 72-96 h for those with a creatinine clearance of 10-29 ml/min. Patients on hemodialysis should take TDF every 7 days following dialysis.
Regarding nonrenal side effects of TDF, there had been some concerns of TDF being associated with a low bone mineral density and fat redistribution [80, 81] . However, a recent study of HIV-infected individuals with 10 years of follow-up did not find any significant changes in both bone mineral density and limb fat [82] . More safety data concerning the significance of nonrenal side effects of TDF in CHB are needed.
TDF is labeled by the US FDA as a category ''B'' pregnancy drug. Animal reproduction studies using doses B19 times the human dose revealed no evidence of impaired fertility or harm to the fetus. There are currently no adequate well-controlled studies of TDF in pregnant woman. However in a follow-up of 3,695 HIV-infected mothers treated with TDF or lamivudine, the incidence of congenital fetal abnormalities was 2.3 and 2.7%, respectively, which was not different from the incidence of congenital abnormalities in NA-naive mothers [83] . Maternal bioavailability may be decreased in the third trimester. Concerning lactation, animal studies have demonstrated that TDF is secreted in milk, and breastfeeding is not advised for mothers taking TDF [84] .
Future directions and conclusions
One interesting phenomenon of TDF is the relatively high HBsAg seroclearance noted in HBeAg-positive CHB patients with genotypes A and D, with a cumulative rate of 10% after 192 weeks of therapy [36] . Given the low incidence of spontaneous and NA-induced HBsAg seroclearance [18, [85] [86] [87] , the possibility of HBsAg seroclearance as a treatment endpoint is finally potentially achievable. Despite this optimism, preliminary studies of TDF in Asians (majority having genotypes B and C) did not achieve HBsAg seroclearance [39] . This could be related to the different immunology of HBV infection in Asians compared to Caucasians, with Asians acquiring the infection at the early stages of life [8] . Further long-term studies in different ethnic groups are needed to address this issue. Additional data of the efficacy of TDF in adefovir-resistant cases and long-term safety profile would also be needed.
In conclusion, with its potent viral suppression, favorable resistance profile, and superior efficacy in lamivudine rescue therapy when compared to adefovir, TDF is perhaps the ''ideal'' first-line drug in the treatment of CHB.
